SingCell

行业

替代蛋白, 生物工艺设备

主题

培养肉与培养海鲜

角色

生产商 — “…a contract development and manufacturing organization (CDMO) for the cultivated meat and stem cell industries…”

尚未被列为已评级方案的供应商。

• 2024-09 最新状态: 据报道，该公司已停业或倒闭。 ↗ ↗ ↗
• 2025-08-21 Singzyme wins 2025 Amgen x NSG Golden Ticket Award | Singapore EDB
  Singzyme, not SingCell, won the 2025 Golden Ticket Programme in Singapore, gaining a one-year residency at NSG BioLabs and access to BSL-2 facilities and Amgen’s network for its PAL site-specific bioconjugation platform. The award highlights support for …
• 2025-08-21 SINGZYME WINS 2025 AMGEN X NSG GOLDEN TICKET FOR BREAKTHROUGH BIOCONJUGATION PLATFORM
  Singzyme (not SingCell) is the 2025 Golden Ticket Programme winner in Singapore, recognized for its PAL (Peptide Asparaginyl Ligase) site-specific conjugation platform that enhances manufacturing of antibody-drug conjugates and other biologics. The award …
• 2025-09-09 Singapore's A*STAR BTI spinoff AuctuCel launches AI platform to slash cell medicine production costs by 80% | News & Articles | AuctuCel
  AuctuCel, a Singapore-based A*STAR BTI spin-off, launched an AI platform called Fluxperior to optimize cell culture media, promising up to 80% cost reductions and faster development for cell therapies and related products. This highlights SingCell’s relevance …
• 2025-08-26 New startup AuctuCel uses AI to slash cell medicine manufacturing costs | PEAK Singapore
  AuctuCel, a Singapore-based biotech spin-off, uses AI-driven Fluxperior to optimize cell-culture nutrition, reducing R&D and manufacturing costs up to 80% and timelines by up to 83, signaling Singapore’s growing role in affordable, scalable cell therapies. …
• 2026-08-05 AuctuCel launches AuctuPrime to reduce biological variability in cell therapy manufacturing - DEI
  AuctuCel states that its AuctuPrime chemically defined culture medium reduces reliance on animal serum and donor-derived human platelets, aiming for more reproducible, scalable cell therapy manufacturing in Singapore’s regenerative medicine ecosystem. It …
• 2026-10-03 TalkMed Group JV Stem Med opens Singapore's first private stem cell bank
  Stem Med (a TalkMed Group–StemCord JV) opens Singapore’s first private stem cell bank, enabling individuals to store their own mesenchymal stem cells from bone marrow or adipose tissue for future therapeutic use; Stem Cord expands its private cord blood …

股权与投资方 2

同类企业

Cell AgriTech · Laurus Bio · Pensées Inc. · KCell Biosciences · IntegriCulture inc.（インテグリカルチャー株式会社） · STeLa · DiverseFarm · NUProtein